Education
About Us
Working with TipRanks
Follow Us
CytoMed Therapeutics Limited (GDTC)
:GDTC
GDTC Stock Chart & Stats
$2.69
-$0.41(-13.85%)
At close: 4:00 PM EST
$2.69
-$0.41(-13.85%)
Day’s Range― - ―
52-Week Range$1.65 - $4.05
Previous CloseN/A
Volume107.31K
Average Volume (3M)139.57K
Market Cap
$28.51M
Enterprise Value$35.99M
Total Cash (Recent Filing)$2.25M
Total Debt (Recent Filing)$385.05K
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Nov 14, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding11,733,712
10 Day Avg. Volume372,560
30 Day Avg. Volume139,569
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)5.97
Price to Sales (P/S)754.46
P/FCF Ratio-14.31
Enterprise Value/Market Cap1.26
Enterprise Value/Revenue139.40
Enterprise Value/Gross Profit127.11
Enterprise Value/Ebitda-17.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CytoMed Therapeutics Limited News
GDTC FAQ
What was CytoMed Therapeutics Limited’s price range in the past 12 months?
CytoMed Therapeutics Limited lowest stock price was $1.65 and its highest was $4.05 in the past 12 months.
What is CytoMed Therapeutics Limited’s market cap?
CytoMed Therapeutics Limited’s market cap is $28.51M.
When is CytoMed Therapeutics Limited’s upcoming earnings report date?
CytoMed Therapeutics Limited’s upcoming earnings report date is Nov 14, 2025 which is in 18 days.
How were CytoMed Therapeutics Limited’s earnings last quarter?
CytoMed Therapeutics Limited released its earnings results on Apr 28, 2025. The company reported -$0.093 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.093.
Is CytoMed Therapeutics Limited overvalued?
According to Wall Street analysts CytoMed Therapeutics Limited’s price is currently Overvalued.
Does CytoMed Therapeutics Limited pay dividends?
CytoMed Therapeutics Limited does not currently pay dividends.
What is CytoMed Therapeutics Limited’s EPS estimate?
CytoMed Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CytoMed Therapeutics Limited have?
CytoMed Therapeutics Limited has 11,733,712 shares outstanding.
What happened to CytoMed Therapeutics Limited’s price movement after its last earnings report?
CytoMed Therapeutics Limited reported an EPS of -$0.093 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.245%.
Which hedge fund is a major shareholder of CytoMed Therapeutics Limited?
Currently, no hedge funds are holding shares in GDTC
Company Description
CytoMed Therapeutics Limited
CytoMed Therapeutics Limited (GDTC) is a biotechnology company focused on the development and commercialization of innovative cell-based therapies. The company operates primarily in the healthcare sector, specializing in advanced therapeutics designed to target and treat various forms of cancer and autoimmune diseases. CytoMed is dedicated to harnessing the power of immunotherapy and regenerative medicine, with a portfolio that includes proprietary technologies for T-cell engineering and cell therapy products aimed at enhancing patient outcomes.
Technical Analysis
Ownership Overview
26.57% Insiders
0.04% Mutual Funds
0.05% Other Institutional Investors
99.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---